Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avid Radiopharmaceuticals has initiated a Phase II clinical trial studying 18F-AV-45, an investigational molecular imaging compound under development for imaging Alzheimer's disease.
Subscribe to our email newsletter
Avid’s 18F-AV-45 is used with positron emission tomography (PET) to allow visualization of the amyloid plaque deposits in the brain that are characteristic of Alzheimer’s disease.
This US Phase II clinical trial of 18F-AV-45 will enroll approximately 200 patients with varying degrees of memory loss at more than 30 centers across the country. The trial involves a single administration of 18F-AV-45 and a PET imaging procedure that is completed in less than one hour.
The study is designed to show how 18F-AV-45 imaging of amyloid plaque compares between healthy volunteers, patients with mild cognitive impairment, and patients with Alzheimer’s disease. This initial Phase II study is reportedly the first of several trials planned to study the effectiveness of this Avid molecular imaging agent in more than 500 patients worldwide.
This is also reportedly the first large-scale multi-center trial of an 18F-labeled PET molecular imaging agent for visualizing amyloid plaques.
Daniel Skovronsky, president and CEO of Avid, said: “The initiation of this study is a major milestone for Avid and what will be a major advance for the field of molecular imaging.”